MyoKardia Company Profile (NASDAQ:MYOK)

About MyoKardia

MyoKardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MYOK
  • CUSIP:
Key Metrics:
  • Previous Close: $16.92
  • 50 Day Moving Average: $19.94
  • 200 Day Moving Average: $14.51
  • 52-Week Range: $27,020,000.00 - $6.24
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.64
  • P/E Growth: 0.00
  • Market Cap: $457.18M
  • Outstanding Shares: 27,020,000
Profitability:
  • Net Margins: -222.21%
  • Return on Equity: -62.91%
  • Return on Assets: -32.99%
Debt:
  • Current Ratio: 6.21%
  • Quick Ratio: 6.21%
Additional Links:
Companies Related to MyoKardia:

Analyst Ratings

Consensus Ratings for MyoKardia (NASDAQ:MYOK) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.50 (38.89% upside)

Analysts' Ratings History for MyoKardia (NASDAQ:MYOK)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
8/9/2016WedbushReiterated RatingOutperform$22.00View Rating Details
7/20/2016BMO Capital MarketsInitiated CoverageOutperform$3.00 -> $28.00View Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuy$16.00 -> $20.00View Rating Details
5/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for MyoKardia (NASDAQ:MYOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016        
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)ViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MyoKardia (NASDAQ:MYOK)
Current Year EPS Consensus Estimate: $-1.52 EPS
Next Year EPS Consensus Estimate: $-1.59 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.34)($0.34)($0.34)
Q3 20161($0.39)($0.39)($0.39)
Q4 20161($0.22)($0.22)($0.22)
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.22)($0.22)($0.22)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MyoKardia (NASDAQ:MYOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MyoKardia (NASDAQ:MYOK)
Insider Ownership Percentage: 46.10%
Institutional Ownership Percentage: 36.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MyoKardia (NASDAQ:MYOK)
DateHeadline
capitalcube.com logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : September 22, 2016 (NASDAQ:MYOK)
www.capitalcube.com - September 22 at 6:00 PM
fxpips.com logoThese Stocks are Falling on Unusual Volume (NASDAQ:MYOK)
www.fxpips.com - September 21 at 10:26 AM
streetinsider.com logoMyoKardia (MYOK) Will Update on MYK-461, MYK-491, Precision Pipeline at R&D Day (NASDAQ:MYOK)
www.streetinsider.com - September 21 at 10:26 AM
4-traders.com logoMYOKARDIA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:MYOK)
www.4-traders.com - September 21 at 10:26 AM
capitalcube.com logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : September 21, 2016 (NASDAQ:MYOK)
www.capitalcube.com - September 21 at 10:26 AM
publicnow.com logoMyoKardia to Host R&D Day on September 21 (NASDAQ:MYOK)
www.publicnow.com - September 14 at 10:35 AM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MYOK)
biz.yahoo.com - September 12 at 6:01 PM
finance.yahoo.com logoMyoKardia to Present at 2016 Wells Fargo Healthcare Conference (NASDAQ:MYOK)
finance.yahoo.com - September 1 at 6:15 PM
finance.yahoo.com logoMyoKardia to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:MYOK)
finance.yahoo.com - August 10 at 9:27 AM
cnbc.com logoMyoKardia reports 2Q loss (NASDAQ:MYOK)
www.cnbc.com - August 9 at 9:31 AM
publicnow.com logoMyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs (NASDAQ:MYOK)
www.publicnow.com - August 9 at 9:31 AM
finance.yahoo.com logoSHaRe Registry Data Published in PNAS Demonstrate the Power of Combining ... (NASDAQ:MYOK)
finance.yahoo.com - July 14 at 9:57 AM
publicnow.com logoSHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy (NASDAQ:MYOK)
www.publicnow.com - July 14 at 8:38 AM
insidermonkey.com logoHere’s What To Look For Ahead Of The Myokardia Inc (MYOK) Phase II (NASDAQ:MYOK)
www.insidermonkey.com - July 12 at 1:09 PM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:MYOK)
biz.yahoo.com - July 11 at 4:13 PM
publicnow.com logoMyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients (NASDAQ:MYOK)
www.publicnow.com - July 11 at 4:13 PM
capitalcube.com logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : June 28, 2016 (NASDAQ:MYOK)
www.capitalcube.com - June 28 at 9:16 AM
4-traders.com logoCetera Financial Group :'s Parent Company Completes Board with Addition of Industry Leading Executives (NASDAQ:MYOK)
www.4-traders.com - June 16 at 6:30 PM
News IconCetera Parent Company Completes Board Of Directors (NASDAQ:MYOK)
www.fa-mag.com - June 16 at 6:30 PM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:MYOK)
biz.yahoo.com - June 8 at 4:24 PM
publicnow.com logoMyoKardia to Present at 2016 UBS Global Healthcare Conference (NASDAQ:MYOK)
www.publicnow.com - May 16 at 7:42 AM
News IconTherapy for obstructive hypertrophic cardiomyopathy receives orphan drug designation (NASDAQ:MYOK)
www.healio.com - May 12 at 10:32 AM
4-traders.com logoMYOKARDIA INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:MYOK)
www.4-traders.com - May 12 at 10:32 AM
publicnow.com logoMyoKardia Reports First Quarter 2016 Financial Results and Operational Progress (NASDAQ:MYOK)
www.publicnow.com - May 12 at 7:57 AM
sg.finance.yahoo.com logoMyoKardia reports 1Q loss (NASDAQ:MYOK)
sg.finance.yahoo.com - May 12 at 7:43 AM
streetinsider.com logoMyoKardia (MYOK) Announces Receipt of Orphan Drug Designation for MYK-461 for Treatment of Symptomatic oHCM (NASDAQ:MYOK)
www.streetinsider.com - May 3 at 10:25 AM
nasdaq.com logoMyoKardia Gets Orphan Drug Designation For MYK-461 For Treatment Of OHCM (NASDAQ:MYOK)
www.nasdaq.com - May 2 at 11:05 AM
finance.yahoo.com logoMyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) (NASDAQ:MYOK)
finance.yahoo.com - May 2 at 7:30 AM
News IconPCSK9 Inhibitors for Statin Intolerance, Early Beta Blockade in AMI Debated (NASDAQ:MYOK)
www.medscape.com - April 15 at 10:30 AM
publicnow.com logoMyoKardia Names Mary Cranston to Board of Directors (NASDAQ:MYOK)
www.publicnow.com - April 13 at 7:43 AM
finance.yahoo.com logoMYOKARDIA INC Financials (NASDAQ:MYOK)
finance.yahoo.com - March 24 at 1:04 PM
capitalcube.com logoMyoKardia, Inc. :MYOK-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:MYOK)
www.capitalcube.com - March 22 at 3:00 PM
4-traders.com logoMyoKardia : reports 4Q loss (NASDAQ:MYOK)
www.4-traders.com - March 19 at 9:19 AM
4-traders.com logoMYOKARDIA : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:MYOK)
www.4-traders.com - March 18 at 9:17 AM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:MYOK)
biz.yahoo.com - March 18 at 8:32 AM
sg.finance.yahoo.com logoMyoKardia reports 4Q loss (NASDAQ:MYOK)
sg.finance.yahoo.com - March 18 at 7:43 AM
finance.yahoo.com logoMyoKardia Reports Fourth Quarter and 2015 Financial Results and Key Milestones (NASDAQ:MYOK)
finance.yahoo.com - March 18 at 7:30 AM
News IconSanofi pledges potential $2.26B for next-gen oral drugs (NASDAQ:MYOK)
www.bioworld.com - March 17 at 9:40 AM
thestreet.com logo5 Breakout Stocks to Buy Off Weakness (NASDAQ:MYOK)
www.thestreet.com - March 11 at 6:10 AM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:MYOK)
biz.yahoo.com - March 8 at 6:10 AM
finance.yahoo.com logoMyoKardia Names Sunil Agarwal, M.D., to Board of Directors, New VPs Strengthen Research and Development (NASDAQ:MYOK)
finance.yahoo.com - March 7 at 7:30 AM
News Icon$100 Billion French Pharma Giant Sanofi says they’re on the “Hunt” for Rare Disease Acquisitions: Here’s who they may be Eyeballing (NASDAQ:MYOK)
www.ssuchronicle.com - March 6 at 8:48 AM
finance.yahoo.com logoMyoKardia to Present at Cowen and Company 36th Annual Health Care Conference (NASDAQ:MYOK)
finance.yahoo.com - March 1 at 8:00 AM
News IconPrecision Medicine Prevents Common Cardiovascular Disease in Mice (NASDAQ:MYOK)
www.biosciencetechnology.com - February 29 at 5:54 PM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Stat (NASDAQ:MYOK)
biz.yahoo.com - February 23 at 11:33 AM
finance.yahoo.com logoMyoKardia Announces Transition of Chief Medical Officer (NASDAQ:MYOK)
finance.yahoo.com - February 23 at 8:00 AM
bizjournals.com logoRedwood City startup snags $45M to take on deadly lung disease (NASDAQ:MYOK)
www.bizjournals.com - February 18 at 5:41 PM
thestreet.com logoIWN's Underlying Holdings Could Mean 27% Gain Potential (NASDAQ:MYOK)
www.thestreet.com - February 11 at 8:21 AM
News IconSudden cardiac death may soon be a thing of past (NASDAQ:MYOK)
timesofindia.indiatimes.com - February 8 at 5:26 PM
News IconPioneering Discovery Could Lead to Preventive Treatment for Sudden Cardiac Death (NASDAQ:MYOK)
www.medindia.net - February 8 at 8:03 AM

Social

MyoKardia (NASDAQ:MYOK) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff